Lumida
/PRTA
⌘K
Prothena Corporation PLC

Prothena Corporation PLC

PRTA
$8.66USD↑+2.24%+0.19 today

MARKET CAP

453.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$8 – $9

52W RANGE

$6
$12

AI Summary

Stalk
TrimMedium

PRTA remains in a Stage 4 decline with a clear lower-high/lower-low sequence and price trading below its major moving averages. The recent short-covering rally has pushed price into declining 9/21/50 EMAs and verging on resistance at the 200DMA, creating an opportune zone to trim bearish positions. With medium- and long-term trends firmly down and overbought short-term indicators, fading this rally into moving-average resistance aligns with the prevailing downtrend.

  • ↑Pipeline’s PRX-12 and Bertamumab anticipate top-line results Q4’24–Q2’25.
  • ↑Closed Q4’23 with $621M cash, extending runway for pivotal trials into 2025.
  • ↓2024 op cash burn estimated at $208–225M strains liquidity runway.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Prothena Corporation plc (NASDAQ: PRTA) is a biotechnology company dedicated to developing novel therapeutics targeting neurodegenerative diseases and rare peripheral amyloid disorders. As a late-stage clinical developer, Prothena focuses on advancing therapies, particularly for Alzheimer's and amyloidosis, positioning itself strategically to address significant unmet medical needs. Prothena leverages strategic partnerships with major pharmaceutical companies while actively developing its pipeline, aiming to become a key player in the biopharmaceutical landscape.

Bull says

  • ↑Pipeline’s PRX-12 and Bertamumab anticipate top-line results Q4’24–Q2’25.
  • ↑Closed Q4’23 with $621M cash, extending runway for pivotal trials into 2025.
  • ↑BMY and Roche partnerships could deliver >$105M milestone payments.
  • ↑Addresses markets with >10M Alzheimer’s and amyloidosis patients globally.
  • ↑Moderate Buy consensus and $20 median price target signal analyst upside.
  • ↑Positive growth factor and low leverage suggest solid financial profile.

Bear says

  • ↓2024 op cash burn estimated at $208–225M strains liquidity runway.
  • ↓Q4’23 net loss of $147M underscores ongoing negative cash flow.
  • ↓Eli Lilly and Biogen intensify competition in Alzheimer’s therapy market.
  • ↓Regulatory review uncertainties risk delaying approval timelines and commercialization.
  • ↓Negative profitability and earnings yield factors highlight returns challenges.
  • ↓PRX-12 trial delays or setbacks could trigger significant stock volatility.

Investment themes with PRTA

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2021 · Mgmt. Guidance

Updated 07-16-2026bullish

Transcript signals

Bull points

  • we're excited by the way the field is setting up, and clearly our mechanism is really relevant in the patient population we are holding the trial in for a firm ale.
  • we're highly encouraged about our firm AL trial and our position, you know, in the disease.
  • it's our intention to wholly own this program and commercialize it ourselves. It's a very leverageable sales call point for us, calling on hematologists. We know where up to 75% of the patients are. They're at 500 centers. So it's a very leverageable call point for us. So we're excited to commercialize it on our own, and we're looking forward to data in 2024.

Bear points

  • The estimated full year 2022 net cash used in operating and investing activities is primarily driven by an estimated net loss of $154 to $170 million, which includes an estimated $32 million of non-cash share-based compensation expense.
Read full transcript analysis ›